Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 19 April 2012 | By Alexander Gaffney, RAC
The US Food and Drug Administration (FDA) is going after doctors in an attempt to protect the pharmaceutical supply chain from more instances of counterfeit medicines, reports Medscape News.
There have been two instances of fake Avastin being found in the US in 2012-one in early April and another in mid-February. Both cases involved doctors deviating from approved suppliers to purchase Avastin from unauthorized wholesalers.
While FDA Commissioner Margaret Hamburg has called for additional anti-counterfeiting authority-which she has called woefully inadequate and outdated-in light of steadily increasing risks, the agency said it will go after doctors in the meantime.
"Clinicians in several states have been warned by FDA to stop purchasing medications from foreign or unlicensed suppliers that sell illegal prescription medication," wrote Medscape News.
FDA has sent out 12 letters to doctors who are reportedly purchasing illegal medications in the hopes that the agency can "minimize the chance of patients receiving a counterfeit, unsafe, or ineffective medication."
"The FDA is emphasizing that medical practices buy directly from manufacturers or licensed US wholesale distributors," explained Medscape News.
Medscape news - FDA Warns Docs Who Buy Meds From Unapproved Sources
Read all Regulatory Focus stories on Avastin
Tags: Distributors, Prescriptions, Wholesalers, Bevacizumab, Doctors, Anti-Counterfeit, Counterfeit, Avastin, Latest News, Hamburg
Regulatory Focus newsletters
All the biggest regulatory news and happenings.